Chapter/Section Purchase

1 Introduction to Research & Analysis Reports
1.1 Circulating Biomarker for Liquid Biopsy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Circulating Biomarker for Liquid Biopsy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Circulating Biomarker for Liquid Biopsy Overall Market Size
2.1 Global Circulating Biomarker for Liquid Biopsy Market Size: 2022 VS 2030
2.2 Global Circulating Biomarker for Liquid Biopsy Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Circulating Biomarker for Liquid Biopsy Players in Global Market
3.2 Top Global Circulating Biomarker for Liquid Biopsy Companies Ranked by Revenue
3.3 Global Circulating Biomarker for Liquid Biopsy Revenue by Companies
3.4 Top 3 and Top 5 Circulating Biomarker for Liquid Biopsy Companies in Global Market, by Revenue in 2022
3.5 Global Companies Circulating Biomarker for Liquid Biopsy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Circulating Biomarker for Liquid Biopsy Players in Global Market
3.6.1 List of Global Tier 1 Circulating Biomarker for Liquid Biopsy Companies
3.6.2 List of Global Tier 2 and Tier 3 Circulating Biomarker for Liquid Biopsy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Circulating Biomarker for Liquid Biopsy Market Size Markets, 2022 & 2030
4.1.2 Circulating Tumor Cells (CTCs)
4.1.3 Circulating Tumor DNA (ctDNA)
4.1.4 Cell-Free DNA (cfDNA)
4.1.5 Extracellular Vesicles (EVs)
4.1.6 Others
4.2 By Type - Global Circulating Biomarker for Liquid Biopsy Revenue & Forecasts
4.2.1 By Type - Global Circulating Biomarker for Liquid Biopsy Revenue, 2018-2023
4.2.2 By Type - Global Circulating Biomarker for Liquid Biopsy Revenue, 2024-2030
4.2.3 By Type - Global Circulating Biomarker for Liquid Biopsy Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Circulating Biomarker for Liquid Biopsy Market Size, 2022 & 2030
5.1.2 Early Cancer Screening
5.1.3 Therapy Selection
5.1.4 Treatment Monitoring
5.1.5 Recurrence Monitoring Orthopedics
5.2 By Application - Global Circulating Biomarker for Liquid Biopsy Revenue & Forecasts
5.2.1 By Application - Global Circulating Biomarker for Liquid Biopsy Revenue, 2018-2023
5.2.2 By Application - Global Circulating Biomarker for Liquid Biopsy Revenue, 2024-2030
5.2.3 By Application - Global Circulating Biomarker for Liquid Biopsy Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Circulating Biomarker for Liquid Biopsy Market Size, 2022 & 2030
6.2 By Region - Global Circulating Biomarker for Liquid Biopsy Revenue & Forecasts
6.2.1 By Region - Global Circulating Biomarker for Liquid Biopsy Revenue, 2018-2023
6.2.2 By Region - Global Circulating Biomarker for Liquid Biopsy Revenue, 2024-2030
6.2.3 By Region - Global Circulating Biomarker for Liquid Biopsy Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Circulating Biomarker for Liquid Biopsy Revenue, 2018-2030
6.3.2 US Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.3.3 Canada Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.3.4 Mexico Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Circulating Biomarker for Liquid Biopsy Revenue, 2018-2030
6.4.2 Germany Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.4.3 France Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.4.4 U.K. Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.4.5 Italy Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.4.6 Russia Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.4.7 Nordic Countries Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.4.8 Benelux Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Circulating Biomarker for Liquid Biopsy Revenue, 2018-2030
6.5.2 China Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.5.3 Japan Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.5.4 South Korea Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.5.5 Southeast Asia Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.5.6 India Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Circulating Biomarker for Liquid Biopsy Revenue, 2018-2030
6.6.2 Brazil Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.6.3 Argentina Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Circulating Biomarker for Liquid Biopsy Revenue, 2018-2030
6.7.2 Turkey Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.7.3 Israel Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.7.4 Saudi Arabia Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
6.7.5 UAE Circulating Biomarker for Liquid Biopsy Market Size, 2018-2030
7 Circulating Biomarker for Liquid Biopsy Companies Profiles
7.1 Abbott Laboratories
7.1.1 Abbott Laboratories Company Summary
7.1.2 Abbott Laboratories Business Overview
7.1.3 Abbott Laboratories Circulating Biomarker for Liquid Biopsy Major Product Offerings
7.1.4 Abbott Laboratories Circulating Biomarker for Liquid Biopsy Revenue in Global Market (2018-2023)
7.1.5 Abbott Laboratories Key News & Latest Developments
7.2 Becton, Dickinson and Company
7.2.1 Becton, Dickinson and Company Company Summary
7.2.2 Becton, Dickinson and Company Business Overview
7.2.3 Becton, Dickinson and Company Circulating Biomarker for Liquid Biopsy Major Product Offerings
7.2.4 Becton, Dickinson and Company Circulating Biomarker for Liquid Biopsy Revenue in Global Market (2018-2023)
7.2.5 Becton, Dickinson and Company Key News & Latest Developments
7.3 GE Healthcare
7.3.1 GE Healthcare Company Summary
7.3.2 GE Healthcare Business Overview
7.3.3 GE Healthcare Circulating Biomarker for Liquid Biopsy Major Product Offerings
7.3.4 GE Healthcare Circulating Biomarker for Liquid Biopsy Revenue in Global Market (2018-2023)
7.3.5 GE Healthcare Key News & Latest Developments
7.4 Epigenomics AG
7.4.1 Epigenomics AG Company Summary
7.4.2 Epigenomics AG Business Overview
7.4.3 Epigenomics AG Circulating Biomarker for Liquid Biopsy Major Product Offerings
7.4.4 Epigenomics AG Circulating Biomarker for Liquid Biopsy Revenue in Global Market (2018-2023)
7.4.5 Epigenomics AG Key News & Latest Developments
7.5 Agilent Technologies
7.5.1 Agilent Technologies Company Summary
7.5.2 Agilent Technologies Business Overview
7.5.3 Agilent Technologies Circulating Biomarker for Liquid Biopsy Major Product Offerings
7.5.4 Agilent Technologies Circulating Biomarker for Liquid Biopsy Revenue in Global Market (2018-2023)
7.5.5 Agilent Technologies Key News & Latest Developments
7.6 Biocept
7.6.1 Biocept Company Summary
7.6.2 Biocept Business Overview
7.6.3 Biocept Circulating Biomarker for Liquid Biopsy Major Product Offerings
7.6.4 Biocept Circulating Biomarker for Liquid Biopsy Revenue in Global Market (2018-2023)
7.6.5 Biocept Key News & Latest Developments
7.7 Affymetrix
7.7.1 Affymetrix Company Summary
7.7.2 Affymetrix Business Overview
7.7.3 Affymetrix Circulating Biomarker for Liquid Biopsy Major Product Offerings
7.7.4 Affymetrix Circulating Biomarker for Liquid Biopsy Revenue in Global Market (2018-2023)
7.7.5 Affymetrix Key News & Latest Developments
7.8 Fluxion Biosciences
7.8.1 Fluxion Biosciences Company Summary
7.8.2 Fluxion Biosciences Business Overview
7.8.3 Fluxion Biosciences Circulating Biomarker for Liquid Biopsy Major Product Offerings
7.8.4 Fluxion Biosciences Circulating Biomarker for Liquid Biopsy Revenue in Global Market (2018-2023)
7.8.5 Fluxion Biosciences Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer